4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-002280
CEO & President sold 269,719 shares at an average $18.66 ($5,032,915)
- CEO & President acquired 269,719 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Brumm Joshua T CEO & President | 2024-01-03 | Option exercise 10b5-1 | +51,183 | $1.03 | $52,718 | 636,154 | D |
| Brumm Joshua T CEO & President | 2024-01-03 | Sale 10b5-1 | −15,382 | $18.34 | $282,106 | 620,772 | D |
| Brumm Joshua T CEO & President | 2024-01-03 | Sale 10b5-1 | −19,775 | $19.03 | $376,318 | 600,997 | D |
| Brumm Joshua T CEO & President | 2024-01-03 | Sale 10b5-1 | −16,026 | $20.50 | $328,533 | 584,971 | D |
| Brumm Joshua T CEO & President | 2024-01-04 | Option exercise 10b5-1 | +18,536 | $1.03 | $19,092 | 603,507 | D |
| Brumm Joshua T CEO & President | 2024-01-04 | Option exercise 10b5-1 | +200,000 | $5.54 | $1,108,000 | 803,507 | D |
| Brumm Joshua T CEO & President | 2024-01-04 | Sale 10b5-1 | −180,235 | $18.40 | $3,316,324 | 623,272 | D |
| Brumm Joshua T CEO & President | 2024-01-04 | Sale 10b5-1 | −38,301 | $19.05 | $729,634 | 584,971 | D |
| Derivatives | |||||||
| Brumm Joshua T CEO & President | 2024-01-03 | Option exercise · Stock option (right to buy) 10b5-1 | −51,183 | 18,536 | D | ||
| Brumm Joshua T CEO & President | 2024-01-04 | Option exercise · Stock option (right to buy) 10b5-1 | −18,536 | 0 | D | ||
| Brumm Joshua T CEO & President | 2024-01-04 | Option exercise · Stock option (right to buy) 10b5-1 | −200,000 | 107,863 | D | ||
| Open-market sales · 269,719 sh · avg $18.66 · $5,032,915 | |||||||
Loading xslF345X05/ownership.xml…